DIPROSALIC OINTMENT

Pays: Canada

Langue: anglais

Source: Health Canada

Ingrédients actifs:

BETAMETHASONE (BETAMETHASONE DIPROPIONATE); SALICYLIC ACID

Disponible depuis:

ORGANON CANADA INC.

Code ATC:

D07XC01

DCI (Dénomination commune internationale):

BETAMETHASONE

Dosage:

0.5MG; 30MG

forme pharmaceutique:

OINTMENT

Composition:

BETAMETHASONE (BETAMETHASONE DIPROPIONATE) 0.5MG; SALICYLIC ACID 30MG

Mode d'administration:

TOPICAL

Unités en paquet:

15G/50G

Type d'ordonnance:

Prescription

Domaine thérapeutique:

ANTI-INFLAMMATORY AGENTS

Descriptif du produit:

Active ingredient group (AIG) number: 0215695004; AHFS:

Statut de autorisation:

APPROVED

Date de l'autorisation:

2021-04-16

Résumé des caractéristiques du produit

_DIPROSALIC_
_®_
_ Lotion and Ointment (Betamethasone Dipropionate and Salicylic Acid)
_
_ _
_Page 1 of 15_
PRODUCT MONOGRAPH
INCLUDING PATIENT MEDICATION INFORMATION
DIPROSALIC
®
Betamethasone Dipropionate and Salicylic Acid Lotion
Betamethasone Dipropionate and Salicylic Acid Ointment
Betamethasone 0.5 mg/g (as Betamethasone Dipropionate) and Salicylic
Acid 20 mg/g
Betamethasone 0.5 mg/g (as Betamethasone Dipropionate) and Salicylic
Acid 30 mg/g
60 mL topical lotion
50 g topical ointment
Topical Corticosteroid and Keratolytic
ORGANON CANADA INC.
16766 route Transcanadienne
Kirkland, Quebec
H9H 4M7
www.organon.ca
Date of Initial Approval:
October 04, 1982
Date of Revision:
April 15, 2021
Submission Control No.: 249786
_ _
_DIPROSALIC_
_®_
_ Lotion and Ointment (Betamethasone Dipropionate and Salicylic Acid)
_
_ _
_Page 2 of 15_
TABLE OF CONTENTS
TABLE OF CONTENTS ..............................................................................................................2
PART I: HEALTH PROFESSIONAL INFORMATION ............................................................3
1
INDICATIONS
....................................................................................................................3
1.1
Pediatrics
....................................................................................................................3
1.2
Geriatrics
....................................................................................................................3
2
CONTRAINDICATIONS ..................................................................................................3
3
DOSAGE AND ADMINISTRATION ...............................................................................3
3.1
Dosing Considerations
...............................................................................................3
3.2
Recommended Dose and Dosage Adjustment
...........................................................3
4
MISSED DOSE ......................................................................................